CO6241107A2 - Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento - Google Patents
Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamentoInfo
- Publication number
- CO6241107A2 CO6241107A2 CO08116211A CO08116211A CO6241107A2 CO 6241107 A2 CO6241107 A2 CO 6241107A2 CO 08116211 A CO08116211 A CO 08116211A CO 08116211 A CO08116211 A CO 08116211A CO 6241107 A2 CO6241107 A2 CO 6241107A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkylene
- cycloalkyl
- alkenylene
- alkyl
- phenyl
- Prior art date
Links
- BFLIOKCEGCUTNH-UHFFFAOYSA-N n-phenyl-1,3-benzoxazol-2-amine Chemical group N=1C2=CC=CC=C2OC=1NC1=CC=CC=C1 BFLIOKCEGCUTNH-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000004450 alkenylene group Chemical group 0.000 abstract 4
- 125000002947 alkylene group Chemical group 0.000 abstract 4
- -1 SCF3 Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004419 alkynylene group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000006681 (C2-C10) alkylene group Chemical group 0.000 abstract 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 1
- 229910006069 SO3H Inorganic materials 0.000 abstract 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006021878A DE102006021878A1 (de) | 2006-05-11 | 2006-05-11 | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6241107A2 true CO6241107A2 (es) | 2011-01-20 |
Family
ID=38371048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO08116211A CO6241107A2 (es) | 2006-05-11 | 2008-10-30 | Acidos carboxilicos sustituidos con fenilaminobenzoxazol metodos para su produccion y su uso como medicamento |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US20090149519A1 (enExample) |
| EP (1) | EP2024347B1 (enExample) |
| JP (1) | JP2009536629A (enExample) |
| KR (1) | KR20090006846A (enExample) |
| CN (1) | CN101437805B (enExample) |
| AR (1) | AR060990A1 (enExample) |
| AU (1) | AU2007250213B2 (enExample) |
| BR (1) | BRPI0711448A2 (enExample) |
| CA (1) | CA2651660A1 (enExample) |
| CO (1) | CO6241107A2 (enExample) |
| CY (1) | CY1113177T1 (enExample) |
| DE (1) | DE102006021878A1 (enExample) |
| DK (1) | DK2024347T3 (enExample) |
| ES (1) | ES2391203T3 (enExample) |
| HR (1) | HRP20120829T1 (enExample) |
| IL (1) | IL195179A0 (enExample) |
| MA (1) | MA30402B1 (enExample) |
| MX (1) | MX2008014102A (enExample) |
| MY (1) | MY148258A (enExample) |
| NO (1) | NO20085068L (enExample) |
| NZ (1) | NZ572692A (enExample) |
| PL (1) | PL2024347T3 (enExample) |
| PT (1) | PT2024347E (enExample) |
| RS (1) | RS52450B (enExample) |
| RU (1) | RU2434003C2 (enExample) |
| SI (1) | SI2024347T1 (enExample) |
| TW (1) | TW200812987A (enExample) |
| UY (1) | UY30338A1 (enExample) |
| WO (1) | WO2007131622A1 (enExample) |
| ZA (1) | ZA200808490B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7465804B2 (en) | 2005-05-20 | 2008-12-16 | Amgen Inc. | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders |
| US7582803B2 (en) | 2005-09-14 | 2009-09-01 | Amgen Inc. | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders |
| EP2061760A1 (en) | 2006-09-07 | 2009-05-27 | Amgen, Inc | Benzo-fused compounds for use in treating metabolic disorders |
| CA2662305C (en) | 2006-09-07 | 2012-04-17 | Amgen Inc. | Heterocyclic gpr40 modulators |
| ES2446419T3 (es) | 2007-04-16 | 2014-03-07 | Amgen, Inc | Moduladores de GPR40 de ácidos bifenilfenoxi, tiofenil y aminofenilpropanoico sustituidos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| US8716283B2 (en) | 2007-11-07 | 2014-05-06 | University Of Massachusetts | Type III secretion inhibitors, analogs and uses thereof |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2798330A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8450350B2 (en) | 2010-05-05 | 2013-05-28 | Infinity Pharmaceuticals, Inc. | Triazoles as inhibitors of fatty acid synthase |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| CN103298469A (zh) | 2010-08-31 | 2013-09-11 | 首尔大学校产学协力财团 | PPARδ激动剂的胎儿重编程的用途 |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| TW201317229A (zh) * | 2011-09-14 | 2013-05-01 | Daiichi Sankyo Co Ltd | 稠合雜環衍生物 |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN105142621A (zh) | 2012-10-24 | 2015-12-09 | 国家健康科学研究所 | 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂 |
| WO2015084692A1 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| US10059667B2 (en) | 2014-02-06 | 2018-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
| EP3273981B1 (en) | 2015-03-24 | 2020-04-29 | INSERM - Institut National de la Santé et de la Recherche Médicale | Method and pharmaceutical composition for use in the treatment of diabetes |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CA3126021A1 (en) | 2019-01-11 | 2020-07-16 | Naegis Pharmaceuticals Inc. | Leukotriene synthesis inhibitors |
| KR102375097B1 (ko) * | 2021-04-01 | 2022-03-17 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1491863A (en) * | 1973-10-23 | 1977-11-16 | Lilly Industries Ltd | 2,5-or 2,6-disubstituted benzoxazoles |
| US4025637A (en) * | 1973-10-23 | 1977-05-24 | Lilly Industries, Ltd. | 2,5 OR 2,6 Disubstituted benzoxazoles |
| US5089514A (en) * | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| US5296486A (en) * | 1991-09-24 | 1994-03-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Leukotriene biosynthesis inhibitors |
| AU675680B2 (en) * | 1992-10-14 | 1997-02-13 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| ATE244717T1 (de) * | 1997-03-14 | 2003-07-15 | Vertex Pharma | Inhibitoren des impdh-enzyms |
| WO2000005223A2 (en) * | 1998-07-23 | 2000-02-03 | Astrazeneca Ab | Heterocyclic derivatives and their use as integrin inhibitors |
| WO2000049005A1 (en) * | 1999-02-16 | 2000-08-24 | Aventis Pharma Limited | Bicyclic compounds and their use as integrin receptor ligands |
| GB0001346D0 (en) * | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
| CA2427750C (en) * | 2000-11-04 | 2011-01-04 | Aventis Pharma Limited | Substituted alkanoic acids |
| CA2430978C (en) * | 2000-12-28 | 2012-05-15 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| GB0401334D0 (en) * | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| US7470712B2 (en) * | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| JP2006056830A (ja) * | 2004-08-20 | 2006-03-02 | Dai Ichi Seiyaku Co Ltd | ２−アリールアミノベンゾオキサゾール誘導体 |
-
2006
- 2006-05-11 DE DE102006021878A patent/DE102006021878A1/de not_active Withdrawn
-
2007
- 2007-04-30 EP EP07724733A patent/EP2024347B1/de active Active
- 2007-04-30 CN CN2007800162659A patent/CN101437805B/zh not_active Expired - Fee Related
- 2007-04-30 DK DK07724733.6T patent/DK2024347T3/da active
- 2007-04-30 KR KR1020087027644A patent/KR20090006846A/ko not_active Ceased
- 2007-04-30 AU AU2007250213A patent/AU2007250213B2/en not_active Expired - Fee Related
- 2007-04-30 JP JP2009508193A patent/JP2009536629A/ja active Pending
- 2007-04-30 WO PCT/EP2007/003806 patent/WO2007131622A1/de not_active Ceased
- 2007-04-30 NZ NZ572692A patent/NZ572692A/en not_active IP Right Cessation
- 2007-04-30 RU RU2008148838/04A patent/RU2434003C2/ru not_active IP Right Cessation
- 2007-04-30 SI SI200731028T patent/SI2024347T1/sl unknown
- 2007-04-30 ES ES07724733T patent/ES2391203T3/es active Active
- 2007-04-30 MX MX2008014102A patent/MX2008014102A/es active IP Right Grant
- 2007-04-30 CA CA002651660A patent/CA2651660A1/en not_active Abandoned
- 2007-04-30 RS RS20120395A patent/RS52450B/sr unknown
- 2007-04-30 MY MYPI20084472A patent/MY148258A/en unknown
- 2007-04-30 PL PL07724733T patent/PL2024347T3/pl unknown
- 2007-04-30 PT PT07724733T patent/PT2024347E/pt unknown
- 2007-04-30 HR HRP20120829TT patent/HRP20120829T1/hr unknown
- 2007-04-30 BR BRPI0711448-6A patent/BRPI0711448A2/pt not_active IP Right Cessation
- 2007-05-09 TW TW096116362A patent/TW200812987A/zh unknown
- 2007-05-09 AR ARP070102008A patent/AR060990A1/es not_active Application Discontinuation
- 2007-05-10 UY UY30338A patent/UY30338A1/es not_active Application Discontinuation
-
2008
- 2008-10-06 ZA ZA200808490A patent/ZA200808490B/xx unknown
- 2008-10-30 CO CO08116211A patent/CO6241107A2/es not_active Application Discontinuation
- 2008-11-05 MA MA31362A patent/MA30402B1/fr unknown
- 2008-11-09 IL IL195179A patent/IL195179A0/en unknown
- 2008-11-10 US US12/267,896 patent/US20090149519A1/en not_active Abandoned
- 2008-12-04 NO NO20085068A patent/NO20085068L/no not_active Application Discontinuation
-
2012
- 2012-10-12 CY CY20121100941T patent/CY1113177T1/el unknown
-
2013
- 2013-07-10 US US13/938,627 patent/US8748465B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068479A1 (es) | (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica | |
| AR060990A1 (es) | Acidos carboxilicos sustituidos con fenilaminobenzoxazol y composiciones farmaceuticas que los contienen, utilizadas para el tratamiento de la diabetes | |
| AR109033A2 (es) | Derivados de 1,4-benzotiepina-1,1-dióxido sustituidos con radicales bencilo, productos farmacéuticos que comprenden estos compuestos y su uso | |
| ES2621140T3 (es) | Compuestos ácido acilamino y preparaciones alimenticias que los contienen | |
| CO6260061A2 (es) | (ciclopropilfenil)feniloxamidas metodo para su produccion y su uso como medicamento | |
| NI201000022A (es) | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. | |
| AR067779A1 (es) | Profarmacos dipeptoides y su uso | |
| CO6270211A2 (es) | Compuestos nuevos 951 un acido bifeniloxipropanoico como modulador de crth2 e intermedios | |
| CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| ECSP099781A (es) | Novedosos compuestos que son inhibidores de erk | |
| ECSP088858A (es) | Uso de bifenilamidas de ácido arilcarboxílico para el tratamiento de semillas | |
| AR086773A1 (es) | Un derivado de cinamida sustituida, el metodo para su preparacion y el uso del mismo | |
| MX2012008533A (es) | Naftiridinas sustituidas y su uso como inhibidores de syk quinasa. | |
| CR10206A (es) | Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1 | |
| CY1117449T1 (el) | Φαινυλιουχα ν-ακυλο παραγωγα αμινων και αμινοξεων, μεθοδοι για την παραγωγη αυτων, μια φαρμακευτικη συνθεση και η χρηση αυτων | |
| ECSP066802A (es) | Nuevas amidas de ácidos carboxílicos como inhibidores del factor xa | |
| ECSP077270A (es) | Ácidos de tiazolo - naftilo | |
| UY29437A1 (es) | Nuevos antagonistas de cgrp | |
| AR069961A1 (es) | Derivados de (aza)indol sustituidos en la posicion 5 utiles en el tratamiento de la inflamacion y el dolor, composiciones farmaceuticas que los comprenden, proceso de preparacion de los mismos y compuestos intermediarios. | |
| UY27853A1 (es) | Difenilazetidinonas sustituidas en grupo acido, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
| AR061973A1 (es) | Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos | |
| AR049883A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparacion, y su empleo como medicamentos | |
| AR061377A1 (es) | Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares. | |
| CO6280480A2 (es) | Ciclopentanos sustituidos que tienen actividad prostaglandina | |
| AR085276A1 (es) | Antagonistas de p2x7r y su uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |